Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
INNOVENT BIO 2024 Total Product Rev. RMB8.2B+, Up 40%+ YoY
Recommend 2 Positive 6 Negative 4 |
||||
|
||||
|
INNOVENT BIO (01801.HK)'s total product revenue for 2024 amounted to more than RMB8.2 billion, representing a robust YoY growth of over 40%, according to INNOVENT BIO's announcement. In 4Q24, the total product revenue reached above RMB2 billion, with a YoY growth of over 25%. The strong performance was mainly attributable to the Company's leading position in oncology area and the continued fast growth of major products including TYVYT (sintilimab injection); and the strong ramp-up momentum of new products. The Group anticipated that 2025 will be a year of significant business growth. While continuously growing the existing product portfolio, the Company will strategically pursue the launch of 6 innovative drugs and the commercialization of product newly included in National Reimbursement Drug List (NRDL). Three novel drugs are anticipated to be launched this year, including Dovbleron (ROS1 inhibitor), Limertinib (EGFR TKI) for lung cancer, and Jaypirca (BTK inhibitor) for hematological malignancies. In addition, SINTBILO (anti-PCSK9 monoclonal antibody) has been included in the updated NRDL effective from 1 January 2025. Meanwhile, mazdutide (GCG/GLP-1 dual receptor agonist), teprotumumab (anti-IGF-1R monoclonal antibody), and picankibart (anti-IL-23p19 monoclonal antibody), are currently under review by the National Medical Products Administration of China (NMPA) for approval. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
